Uniphar has expanded its operations with the launch of three facilities in key markets that will allow the company to more effectively deliver specialist services and solutions to its pharmaceutical and medical technology manufacturing partners.
The new facilities are located in Raleigh, NC; Lelystad, Netherlands; and Dublin, Ireland. The North Carolina facility occupies 65,000 square feet and is a Good Manufacturing Practice and Good Distribution Practice pharma-grade storage facility designed to handle ambient, cold-chain, and freezer storage requirements. It includes dedicated clean rooms for clinical trials, a DEA-approved controlled drugs vault for controlled drugs (Schedule II to V), and a fully integrated warehouse management system. The facility is equipped with redundant power supply, temperature & humidity monitoring systems, and advanced inventory management, ensuring compliance with FDA, ISO, and DSCSA regulations.
The facility in the Netherlands, which is Uniphar’s flagship facility in Europe, covers over 96,000 square feet. It is a Grade A facility with narrow-aisle high-bay racking, controlled ambient storage, and segregated quarantine zones. It is also built with sustainable features, including solar energy and a triple redundant power supply, designed to minimize environmental impact.
The facility in Ireland features over 300,000 square feet of space and is designed to support growing demand for Uniphar’s cold-chain logistics. It offers 1,100 pallets of cold storage capacity and is built to LEED Gold standards for sustainable design and operations. The layout is designed to optimize material flows and includes segregated zones for quarantine, recall, and returns management.
According to the company, the new locations are essential for delivering critical therapies to patients while helping pharma companies navigate market access challenges, from clinical trials to global product launches. Uniphar will also be able to deliver logistical solutions for specialty medicines, biologics, and advanced therapies from its facilities.
“These expansions are a direct response to the increasing complexity of launching innovative therapies in diverse and often challenging global markets,” said Dermot Ryan, Uniphar’s COO. “Uniphar’s ability to provide end-to-end solutions, from clinical trial support to product launch and distribution, is what sets us apart as a leader in the global pharmaceutical logistics and supply chain space. This milestone reflects our commitment to driving excellence in pharmaceutical logistics and underscores our long-term strategy to support the development and delivery of innovative therapies globally.”
Besides the new facilities, Uniphar’s global network now encompasses 22 strategically located facilities across Europe, North America, and other regions.
